Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
abbreviated, Alaven, aminosalicylate, analyze, analyzed, ANDA, andC, Answer, apriso, Arcolab, arisen, auction, Australia, banker, bear, Bergamo, bioavailability, bioequivalence, black, box, boxed, budesonide, Catalent, CDC, citing, climate, collateral, collateralize, confirming, context, contrary, corroborated, Cosma, counter, Counterclaim, Court, crofelemer, Debtor, declaratory, denial, denied, deposit, designee, District, economy, EITF, eleven, embedded, ensuing, exceeding, expressly, family, foam, foregoing, fundamental, gastroesophageal, Glenmark, goal, guide, headcount, HIV, indenture, India, injury, interruption, IV, Jersey, junior, Kentucky, knowledge, lawsuit, lead, linked, Metozolv, mid, mitigation, mix, Mumbai, Nap, Napo, neuropsychiatric, nonrefundable, Obama, OSP, Paragraph, permission, Pharmatel, pivotal, political, preceding, predecessor, prevalent, principle, protocol, PTY, rank, redeem, redeemed, refinanced, repurchase, repurchased, retrospectively, saleable, scientifically, semiannually, South, spectrum, subordinated, substantive, suitable, suspended, Swindon, thereof, TID, timeline, treasury, trustee, unamortized, unenforceability, vigorously, waive, Winchester, Wuppertal, Zealand
Removed:
acceleration, achieved, area, assuming, Austria, belief, deliver, Denmark, diseased, Finland, forma, GAAP, Iceland, implemented, Ireland, light, Luxembourg, merger, model, negotiation, Norway, predominate, pro, ranging, Republic, Schwartz, Schwarz, site, stocking, studying, Sweden, thereon, training, UCB, unqualified, unvested, utility, volatility
Filing tables
Filing exhibits
- 10-K Annual report
- 10.64 Collaboration Agreement Between Napo Pharmaceuticals and Salix
- 10.65 Manufacturing and Supply Agreement Between Salix and Glenmark
- 21.1 Salix Pharmaceuticals, LTD. Subsidiaries
- 23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 Consent of Ernst & Young LLP
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Related press release
Salix Pharmaceuticals similar filings
Filing view
External links
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Salix Pharmaceuticals, Ltd. (the “Company”) for the period ended December 31, 2008 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Adam C. Derbyshire, Senior Vice President, Finance and Administration and Chief Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report. |
| /s/ Adam C. Derbyshire |
Adam C. Derbyshire |
Senior Vice President, Finance & Administration, and Chief Financial Officer |
March 11, 2009 |